Daclatasvir + Sirolimus = Unknown or no reaction

Effect on Concentration

Daclatasvir
No change
Applies within class?
No
Sirolimus
No change
Applies within class?
No

Pharmacologic Effects

Daclatasvir
Effect
N/A
Applies within class?
No
Sirolimus
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 18-Jul-2018

Summary

The interaction between sirolimus and daclatasvir has not been formally studied, but information can be drawn from other sources.

Sources

Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. ^

Study Design

In this study the drug-drug interaction potential of daclatasvir (DCV) with tacrolimus was assessed. Tacrolimus was administered as a 5mg single dose and daclatasvir was given as 60mg QD.

Study Results

Using geometric mean ratios (GMR) and 90% confidence intervals (CI), the Cmax, Cmin and AUC for DCV was 1.07 (1.02-1.12), 1.10 (1.03-1.19) and 1.05 (1.03-1.07), while the Cmax and AUC for tacrolimus was 1.05 (0.90-1.23) and 1.00 (0.88-1.13), respectively.

Study Conclusions

Tacrolimus exposure was not affected by coadministration with DCV. The manufacturer states that no dose adjustment is required.

References

Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug interactions with direct-acting antivirals for hepatitis c: implications for hiv and transplant patients. Annals Of Pharmacotherapy. 2015; 6: 674-687.